Management of cystic fibrosis-related diabetes

O’Riordan, Stephen; Robinson, Paul D.; Donaghue, Kim C.; Moran, Antoinette

doi:10.1111/j.1399-5448.2008.00437.x

Cited by 64 publications

(56 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…49,[166][167][168] As regards whether or not to start at the IGT stage, most agree there are insufficient data on the management of CFRIGT patients to support guidelines. 68,167,168 Brennan et al 164 felt that when CFRD without FH or IGT is identified, it is not known whether or not benefits of treatment outweigh the burden of management and at which point treatment should be initiated.…”

Section: Overview Of Review Articles Of Cystic Fibrosis-related Diabementioning

confidence: 99%

“…1,7,63,68,[164][165][166][167][168] Most conclude that insulin is the treatment of choice. Some recommended that insulin should be initiated when CFRD is diagnosed.…”

Section: Overview Of Review Articles Of Cystic Fibrosis-related Diabementioning

confidence: 99%

“…1,164 However, it was noted that despite data from other populations suggesting that insulin may be beneficial in maintaining euglycaemia during infection, no studies have examined the benefits of such in hospitalised patients with CF. 168 Dobson et al believed further prospective randomised control trials are required to investigate the benefits of insulin therapy after the diagnosis of CFRD. 49 They also pointed out some drawbacks of insulin therapy, such as compliance problems and the increased risk of hypoglycaemia.…”

Section: Overview Of Review Articles Of Cystic Fibrosis-related Diabementioning

confidence: 99%

“…49 They also pointed out some drawbacks of insulin therapy, such as compliance problems and the increased risk of hypoglycaemia. O'Riordan et al 168 in the ISPAD guidelines recommended that 'the decision to treat should be based on consideration of BG levels and the impact of treatment on the individual's overall condition' .…”

Section: Overview Of Review Articles Of Cystic Fibrosis-related Diabementioning

confidence: 99%

See 3 more Smart Citations

Screening for cystic fibrosis-related diabetes: a systematic review.

Waugh

Royle²,

Craigie³

et al. 2012

Health Technol Assess

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service' . The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects...

show abstract

Section: Overview Of Review Articles Of Cystic Fibrosis-related Diabementioning

confidence: 99%

“…1,7,63,68,[164][165][166][167][168] Most conclude that insulin is the treatment of choice. Some recommended that insulin should be initiated when CFRD is diagnosed.…”

Section: Overview Of Review Articles Of Cystic Fibrosis-related Diabementioning

confidence: 99%

Section: Overview Of Review Articles Of Cystic Fibrosis-related Diabementioning

confidence: 99%

Section: Overview Of Review Articles Of Cystic Fibrosis-related Diabementioning

confidence: 99%

See 2 more Smart Citations

Screening for cystic fibrosis-related diabetes: a systematic review.

Waugh

Royle²,

Craigie³

et al. 2012

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…In previous recommendations, patients without fasting hyperglycemia were not indicated for insulin therapy (12,14), but more recent studies have shown the benefits of the early treatment of CFRD with insulin for both groups (with or without fasting hyperglycemia), thus justifying that it is unnecessary to separate the two groups, or to alter the diagnostic classification (7,18).…”

Section: Definition and Diagnosis Of Cfrd -An Evolving Visionmentioning

confidence: 99%

Update on diagnosis and monitoring of cystic fibrosis-related diabetes mellitus (CFRD)

Noronha

Calliari

Damaceno

et al. 2011

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Cystic fibrosis (CF) is the most common recessive autosomal disease among Caucasian. Children with CF have benefitted from advances in medical and nutritional treatments, and this can be gleaned from the improvement in the survival of these patients. The increase in the survival rate brought with it the appearance of co-morbidities related to CF. Nowadays cystic fibrosis-related diabetes (CFRD) is considered the most common complication associated with CF. It can appear as early as infancy or adolescence, and its prevalence can be as high as 50% in adult patients. Because of its high prevalence, difficulties in early detection and the risks involved, in recent years several studies and consensuses have focused on this condition, adding information about the epidemiology, pathophysiology, prognosis and treatment of CFRD. The main aspects of these new concepts, as well as the current recommendations for its diagnosis and follow-up, will be presented in this study.

show abstract

Cystic fibrosis‐related diabetes

Watson

2015

Advanced Nutrition and Dietetics in Diabetes

View full text Add to dashboard Cite

Management of cystic fibrosis-related diabetes

Cited by 64 publications

References 55 publications

Screening for cystic fibrosis-related diabetes: a systematic review.

Screening for cystic fibrosis-related diabetes: a systematic review.

Update on diagnosis and monitoring of cystic fibrosis-related diabetes mellitus (CFRD)

Cystic fibrosis‐related diabetes

Contact Info

Product

Resources

About